Price T Rowe Associates Inc. MD grew its position in shares of Zai Lab Limited (NASDAQ:ZLAB – Get Rating) by 9.6% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,607,681 shares of the company’s stock after acquiring an additional 141,271 shares during the quarter. Price T Rowe Associates Inc. MD owned 1.64% of Zai Lab worth $54,983,000 at the end of the most recent reporting period.
A number of other hedge funds have also added to or reduced their stakes in the business. Krane Funds Advisors LLC increased its position in shares of Zai Lab by 1.7% in the third quarter. Krane Funds Advisors LLC now owns 40,885 shares of the company’s stock valued at $1,398,000 after acquiring an additional 694 shares during the last quarter. Ensign Peak Advisors Inc boosted its holdings in shares of Zai Lab by 7.3% in the 3rd quarter. Ensign Peak Advisors Inc now owns 5,850 shares of the company’s stock valued at $200,000 after buying an additional 400 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Zai Lab by 7.7% in the third quarter. Bank of New York Mellon Corp now owns 88,957 shares of the company’s stock valued at $3,043,000 after buying an additional 6,367 shares in the last quarter. Bellevue Group AG acquired a new position in Zai Lab during the third quarter worth $1,278,000. Finally, Macquarie Group Ltd. lifted its stake in Zai Lab by 21.7% in the third quarter. Macquarie Group Ltd. now owns 6,162 shares of the company’s stock valued at $211,000 after acquiring an additional 1,098 shares during the last quarter. Institutional investors own 59.46% of the company’s stock.
Wall Street Analyst Weigh In
Separately, JPMorgan Chase & Co. dropped their target price on shares of Zai Lab from $96.00 to $79.00 and set an “overweight” rating on the stock in a report on Friday, November 18th.
Insider Transactions at Zai Lab
Zai Lab Price Performance
Shares of ZLAB opened at $31.70 on Tuesday. The company’s 50-day moving average is $40.15 and its 200-day moving average is $36.89. Zai Lab Limited has a fifty-two week low of $20.98 and a fifty-two week high of $53.95.
Zai Lab Company Profile
Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.
- Get a free copy of the StockNews.com research report on Zai Lab (ZLAB)
- First Republic: First Rate Risk or Time To Buy?
- These Hedge Funds Are Getting Crushed By SVB
- Buy The Dip In The Charles Schwab Corporation
- ZIM Integrated Shipping Services: Up 15% But Don’t Chase It
- FedEx Is A Buy Going Into Earnings
Want to see what other hedge funds are holding ZLAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zai Lab Limited (NASDAQ:ZLAB – Get Rating).
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.